David A. Siegel Gamida Cell Ltd. Transaction History

Two Sigma Advisers, LP

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$1.73 - $4.29 $21,106 - $52,338	-12,200 Closed	0 $0
Q1 2022 May 16, 2022	SELL	$2.22 - $4.47 $49,950 - $100,575	-22,500 Reduced 64.84%	12,200 $51,000
Q4 2021 Feb 14, 2022	BUY	$2.2 - $4.46 $19,360 - $39,248	8,800 Added 33.98%	34,700 $88,000
Q3 2021 Nov 15, 2021	SELL	$3.85 - $6.44 $95,865 - $160,356	-24,900 Reduced 49.02%	25,900 $102,000
Q2 2021 Aug 16, 2021	BUY	$5.85 - $8.33 $76,050 - $108,290	13,000 Added 34.39%	50,800 $326,000
Q1 2021 May 17, 2021	SELL	$7.8 - $12.43 $55,380 - $88,253	-7,100 Reduced 15.81%	37,800 $306,000
Q4 2020 Feb 16, 2021	SELL	$4.07 - $11.0 $31,339 - $84,700	-7,700 Reduced 14.64%	44,900 $377,000
Q3 2020 Nov 16, 2020	BUY	$3.93 - $4.59 $143,052 - $167,076	36,400 Added 224.69%	52,600 $218,000
Q2 2020 Aug 14, 2020	BUY	$2.79 - $6.5 $45,198 - $105,300	16,200 New	16,200 $74,000

2.2K

Ticker GMDA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 76,319,600
Market Cap $2.29M
Description
Gamida Cell Ltd., a clinical-stage biopharmaceutical company, develops cell therapies to cure blood cancers and serious hematologic diseases. The company's lead product candidate is omidubicel, a cell therapy that has completed Phase III clinical trial in patients with high-risk hematologic malignancies, as well as in Phase I/II clinical trials ...

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.